(−)-Epicatechin Rescues Memory Deficits by Activation of Autophagy in a Mouse Model of Tauopathies

Abstract

In tauopathies, defects in autophagy-lysosomal protein degradation are thought to contribute to the abnormal accumulation of aggregated tau. Recent studies have shown that (−)-Epicatechin (Epi), a dietary flavonoid belonging to the flavan-3-ol subgroup, improves blood flow, modulates metabolic profiles, and prevents oxidative damage. However, less research has explored the effects of Epi on tauopathies. Here, we found that Epi rescued cognitive deficits in P301S tau transgenic mice, a model exhibiting characteristics of tauopathies like frontotemporal dementia and Alzheimer's disease, and attenuated tau pathology through autophagy activation. Proteomic and biochemical analyses revealed that P301S mice exhibit deficits in autophagosome formation via modulating mTOR, consequently inhibiting autophagy. Epi inhibited the mTOR signaling pathway to promote autophagosome formation, which is essential for the clearance of tau aggregation. By using chloroquine (CQ) to inhibit autophagy in vivo, we further confirmed that Epi induced tau degradation via the autophagy pathway. Lastly, Epi administration was also found to improve cognition by reversing spine decrease and neuron loss, as well as attenuating neuroinflammation. Our findings suggest that Epi promoted tau clearance by activating autophagy, indicating its potential as a promising therapeutic candidate for tauopathies.

Keywords

autophagy / (−)-Epicatechin / FTDP / memory deficits / tauopathies

References

[1] Y. Wang and E. Mandelkow, “Tau in Physiology and Pathology,” Nature Reviews Neuroscience 17, no. 1 (2016): 5-21.

[2] C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones, “Alzheimer's Disease,” Lancet 377, no. 9770 (2011): 1019-1031.

[3] C. Ballatore, V. M. Lee, and J. Q. Trojanowski, “Tau-Mediated Neurodegeneration in Alzheimer's Disease and Related Disorders,” Nature Reviews Neuroscience 8, no. 9 (2007): 663-672.

[4] K. A. Josephs, M. E. Murray, N. Tosakulwong, et al., “Tau Aggregation Influences Cognition and Hippocampal Atrophy in the Absence of Beta-Amyloid: A Clinico-Imaging-Pathological Study of Primary Age-Related Tauopathy (PART),” Acta Neuropathologica 133, no. 5 (2017): 705-715.

[5] D. S. Knopman, H. Amieva, R. C. Petersen, et al., “Alzheimer Disease,” Nature Reviews Disease Primers 7, no. 1 (2021): 33.

[6] V. A. Polito, H. Li, H. Martini-Stoica, et al., “Selective Clearance of Aberrant Tau Proteins and Rescue of Neurotoxicity by Transcription Factor EB,” EMBO Molecular Medicine 6, no. 9 (2014): 1142-1160.

[7] Q. L. Ma, X. Zuo, F. Yang, et al., “Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice,” Journal of Biological Chemistry 288, no. 6 (2013): 4056-4065.

[8] M. J. Lee, J. H. Lee, and D. C. Rubinsztein, “Tau Degradation: The Ubiquitin-Proteasome System Versus the Autophagy-Lysosome System,” Progress in Neurobiology 105 (2013): 49-59.

[9] I. Dikic and Z. Elazar, “Mechanism and Medical Implications of Mammalian Autophagy,” Nature Reviews Molecular Cell Biology 19, no. 6 (2018): 349-364.

[10] S. Jiang and K. Bhaskar, “Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy,” Frontiers in Molecular Neuroscience 13 (2020): 586731.

[11] V. Schaeffer, I. Lavenir, S. Ozcelik, M. Tolnay, D. T. Winkler, and M. Goedert, “Stimulation of Autophagy Reduces Neurodegeneration in a Mouse Model of Human Tauopathy,” Brain: A Journal of Neurology 135, no. 7 (2012): 2169-2177.

[12] S. Ozcelik, G. Fraser, P. Castets, et al., “Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice,” PLoS ONE 8, no. 5 (2013): e62459.

[13] U. Krüger, Y. Wang, S. Kumar, and E.-M. Mandelkow, “Autophagic Degradation of Tau in Primary Neurons and Its Enhancement by Trehalose,” Neurobiology of Aging 33, no. 10 (2012): 2291-2305.

[14] E. E. Congdon, J. W. Wu, N. Myeku, et al., “Methylthioninium Chloride (Methylene Blue) Induces Autophagy and Attenuates Tauopathy in Vitro and in Vivo,” Autophagy 8, no. 4 (2012): 609-622.

[15] P. Delobel, I. Lavenir, G. Fraser, et al., “Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy,” American Journal of Pathology 172, no. 1 (2008): 123-131.

[16] T. Jiang, Y. D. Zhang, Q. Chen, et al., “TREM2 Modifies Microglial Phenotype and Provides Neuroprotection in P301S Tau Transgenic Mice,” Neuropharmacology 105 (2016): 196-206.

[17] Y. Q. Zeng, Y. J. Wang, and X. F. Zhou, “Effects of (-)Epicatechin on the Pathology of APP/PS1 Transgenic Mice,” Frontiers in Neurology 5 (2014): 69.

[18] G. Borges, J. I. Ottaviani, J. J. J. van der Hooft, H. Schroeter, and A. Crozier, “Absorption, Metabolism, Distribution and Excretion of (−)-Epicatechin: A Review of Recent Findings,” Molecular Aspects of Medicine 61 (2018): 18-30.

[19] A. Faria, D. Pestana, D. Teixeira, et al., “Insights Into the Putative Catechin and Epicatechin Transport Across Blood-Brain Barrier,” Food & Function 2, no. 1 (2011): 39-44.

[20] B. Dejanovic, M. A. Huntley, A. De Mazière, et al., “Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies,” Neuron 100, no. 6 (2018): 1322-1336. e1327.

[21] M. Artemenko, S. S. W. Zhong, S. K. Y. To, and A. S. T. Wong, “p70 S6 Kinase as a Therapeutic Target in Cancers: More Than Just an mTOR Effector,” Cancer Letters 535 (2022): 215593.

[22] C. Xu, X. Pan, D. Wang, et al., “O-GlcNAcylation of Raptor Transduces Glucose Signals to mTORC1,” Molecular Cell 83, no. 16 (2023): 3027-3040.

[23] P. I. Oteiza, C. G. Fraga, and M. Galleano, “Linking Biomarkers of Oxidative Stress and Disease With Flavonoid Consumption: From Experimental Models to Humans,” Redox Biology 42 (2021): 101914.

[24] Z. Qu, A. Liu, P. Li, et al., “Advances in Physiological Functions and Mechanisms of (−)-Epicatechin,” Critical Reviews in Food Science and Nutrition 61, no. 2 (2021): 211-233.

[25] V. Navarrete-Yañez, A. Garate-Carrillo, A. Rodriguez, et al., “Effects of (−)-Epicatechin on Neuroinflammation and Hyperphosphorylation of Tau in the Hippocampus of Aged Mice,” Food & Function 11, no. 12 (2020): 10351-10361.

[26] K. L. Hole, L. E. Staniaszek, G. Menon Balan, J. M. Mason, J. T. Brown, and R. J. Williams, “Oral (−)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3β,” Frontiers in Neuroscience 15 (2021): 697319.

[27] J. Bockaert and P. Marin, “mTOR in Brain Physiology and Pathologies,” Physiological Reviews 95, no. 4 (2015): 1157-1187.

[28] D. H. Kim, D. D. Sarbassov, S. M. Ali, et al., “mTOR Interacts With Raptor to Form a Nutrient-Sensitive Complex That Signals to the Cell Growth Machinery,” Cell 110, no. 2 (2002): 163-175.

[29] A. He, X. Chen, M. Tan, et al., “Acetyl-CoA Derived From Hepatic Peroxisomal β-Oxidation Inhibits Autophagy and Promotes Steatosis via mTORC1 Activation,” Molecular Cell 79, no. 1 (2020): 30-42. e34.

[30] D. M. Gwinn, D. B. Shackelford, D. F. Egan, et al., “AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint,” Molecular Cell 30, no. 2 (2008): 214-226.

[31] M. F. Schmidt, Z. Y. Gan, D. Komander, and G. Dewson, “Ubiquitin Signalling in Neurodegeneration: Mechanisms and Therapeutic Opportunities,” Cell Death and Differentiation 28, no. 2 (2021): 570-590.

[32] F. M. Menzies, A. Fleming, A. Caricasole, et al., “Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities,” Neuron 93, no. 5 (2017): 1015-1034.

[33] K. Moreau, A. Fleming, S. Imarisio, et al., “PICALM Modulates Autophagy Activity and Tau Accumulation,” Nature Communications 5 (2014): 4998.

[34] A. S. Moore and E. L. Holzbaur, “Dynamic Recruitment and Activation of ALS-Associated TBK1 With Its Target Optineurin Are Required for Efficient Mitophagy,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 24 (2016): E3349-3358.

[35] Y. Xu, S. Zhang, and H. Zheng, “The Cargo Receptor SQSTM1 Ameliorates Neurofibrillary Tangle Pathology and Spreading Through Selective Targeting of Pathological MAPT (Microtubule Associated Protein Tau),” Autophagy 15, no. 4 (2019): 583-598.

[36] J. Niu, T. Yan, W. Guo, et al., “The COPS3-FOXO3 Positive Feedback Loop Regulates Autophagy to Promote Cisplatin Resistance in Osteosarcoma,” Autophagy 19, no. 6 (2023): 1693-1710.

[37] X. Zhang, M. Wei, J. Fan, et al., “Ischemia-Induced Upregulation of Autophagy Preludes Dysfunctional Lysosomal Storage and Associated Synaptic Impairments in Neurons,” Autophagy 17, no. 6 (2021): 1519-1542.

[38] L. Yu, C. K. McPhee, L. Zheng, et al., “Termination of Autophagy and Reformation of Lysosomes Regulated by mTOR,” Nature 465, no. 7300 (2010): 942-946.

[39] S. Cao, W. B. Shen, E. A. Reece, and P. Yang, “Deficiency of the Oxidative Stress-Responsive Kinase p70S6K1 Restores Autophagy and Ameliorates Neural Tube Defects in Diabetic Embryopathy,” American Journal of Obstetrics and Gynecology 223, no. 5 (2020): 753. e714-e751.

[40] M. Dumont, C. Stack, C. Elipenahli, et al., “Behavioral Deficit, Oxidative Stress, and Mitochondrial Dysfunction Precede Tau Pathology in P301S Transgenic Mice,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 25, no. 11 (2011): 4063-4072.

[41] L. Wang, M. Liu, J. Gao, et al., “Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline,” Journal of Alzheimer's Disease 84, no. 3 (2021): 1057-1069.

[42] C. K. Yip, K. Murata, T. Walz, D. M. Sabatini, and S. A. Kang, “Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition,” Molecular Cell 38, no. 5 (2010): 768-774.

[43] J. Li, S. G. Kim, and J. Blenis, “Rapamycin: One Drug, Many Effects,” Cell Metabolism 19, no. 3 (2014): 373-379.

[44] C. F. Haskell-Ramsay, P. A. Jackson, J. S. Forster, F. L. Dodd, S. L. Bowerbank, and D. O. Kennedy, “The Acute Effects of Caffeinated Black Coffee on Cognition and Mood in Healthy Young and Older Adults,” Nutrients 10, no. 10 (2018): 1386.

[45] Y. Yoshiyama, M. Higuchi, B. Zhang, et al., “Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model,” Neuron 53, no. 3 (2007): 337-351.

[46] Z. Zhang, H. Wu, and H. Huang, “Epicatechin Plus Treadmill Exercise Are Neuroprotective Against Moderate-Stage Amyloid Precursor Protein/Presenilin 1 Mice,” Pharmacognosy Magazine 12, no. Suppl 2 (2016): S139-146.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.